It has been demonstrated that IL-8 monoclonal antibody can suppress tumor angiogenesis (Figure 5), significantly reduce tumor size in vitro and animal models (114, 115), and decrease recruitment of MDSCs to the tumor (116). Here, CXCL8 is linked to neoplasm.